Αρχική World News Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients... World News Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer Από Ogkologos - 18 Νοεμβρίου, 2024 1050 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Do Black Lives Matter Less Than Those of Cancer Survivors? 18 Ιουνίου, 2020 Study Suggests Reviewing Lung Cancer Screening Criteria for African Americans 31 Ιουλίου, 2019 Bagel Shop Owner Shaves Head To Support 10-Year-Old Customer 27 Οκτωβρίου, 2021 How My Cancer Diagnosis at Age 17 Changed My Perspective on... 14 Δεκεμβρίου, 2020 Φόρτωση περισσοτέρων HOT NEWS Why ASCO’s Annual Meeting Matters for People With Cancer and How... Family Starts “Dancing While Cancering” To Honor Their Daughter’s Joyful Memory. EMA Recommends Granting a Marketing Authorisation for Relugolix How TRACERx is helping us predict lung cancer’s next move